Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy

American Journal of Gastroenterology

Volumn 94, Issue 2, 1999, Pages 489-496

  Sakaida, Isao ^a   Nagatomi, Atsuko ^a   Hironaka, Koji ^a   Uchida, Koichi ^a   Okita, Kiwaniu ^a  

^a YAMAGUCHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA ACTIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STELLATE CELL;

ACTINS; ADULT; ANTIVIRAL AGENTS; BIOPSY; CASE-CONTROL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTERFERON TYPE I, RECOMBINANT; INTERFERON-ALPHA; INTERFERON-BETA; LIVER; LIVER CIRRHOSIS; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; MUSCLE, SMOOTH;

EID: 0033082888     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1999.884_m.x     Document Type: Article

References (35)

1. Rojkind M, Giambrone M-A, Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology 1979;76:710-9.
2. Friedman SL. The cellular basis of hepatic fibrosis. N Engl J Med 1993;328:1828-35.
3. Pinzani M. Hepatic stellate (Ito) cells: expanding roles for a liverspecific pericyte. J Hepatol 1995;22:700-6.
4. Bhunchet E, Wake K. Role of mesenchymal cell populations in porcine-serum-induced rat liver fibrosis. Hepatology 1992:16:1452-73.
5. French SW, Miyamoto K, Wong K, et al. Role of the Ito cell in liver parenchymal fibrosis in rats fed alcohol and a high fat-low protein diet. Am J Pathol 1988;132:73-85.
6. Milani S, Herbst H, Schuppan D, et al. In situ hybridization for procollagen types I, III, and IV mRNA in normal and fibrotic rat liver: Evidence for predominant expression in non-parenchymal cells. Hepatology 1989:10:84-92.
7. Milani S, Herbst H, Schuppan D, et al. Cellular localization of type I, III, and IV procollagen gene transcripts in normal and fibrotic human liver. Am J Pathol 1990; 137:59-70.
8. Geerts A, Lazou JM, Bleser P, et al. Tissue distribution, quantitation, and proliferation kinetics of fat-storing cells in carbon-tetrachlorideinjured rat liver. Hepatology 1991; 13:1193-1202.
9. Mancini R, Jezequel AM, et al. Quantitative analysis of proliferating sinusoidal cells in dimethylnitrosoamine-induced cirrhosis. An immuno-histochemical study. J Hepatol 1992:15:362-6.
10. Enzan H, Himeno H, Iwamura S, et al. Immunohistochemical identification of Ito cells and their myofibroblastic transformation in adult human liver. Virchows Arch 1994;424:249-56.
11. Schmitt-Graff A, Kruger S, Bochard F, et al. Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol 1991;138:1233-42.
12. Skalli O, Ropraz P, Trzeciak A, et al. A monoclonal antibody against a-smooth muscle actin: A new probe for smooth muscle differentiation. J Cell Biol 1986:103:2787-96.
13. Geerts A, Vrijsen R, Rauterberg J, et al. In vitro differentiation of fat-storing cells parallels marked increase of collagen synthesis and secretion. J Hepatol 1989;9:59-68.
14. Yamaoka K, Toshihiko N, Marumoto F, et al. a-Smooth muscle actin expression in normal and fibrotic human livers. Dig Dis Sei 1993;8: 1473-9.
15. Czaja MJ, Weiner FR, Takahashi S, et al. r-Interferon treatment inhibits collagen deposition in murine schistosomiasis. Hepatology 1989:10:795-800.
16. Baroni GS, D'Ambrosio L, Curto P, et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 1996:23:1189-99.
17. Mallat A, Preaux AM, Blazejewski S, et al. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995;21:1003-10.
18. Okazaki M, Hino K, Fujii K, et al. Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Dig Dis Sei 1996;41:2453-8.
19. Sweat F, Puchtler H, Rosenthal SI. Sirius red F3BA as a stain for connective tissue. Arch Pathol 1964;78:69-72.
20. Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991:13:372-4.
21. Sakaida I, Matsumura Y, Kubota M, et al. The prolyl 4-hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in the rat liver fibrosis induced by choline deficient L-amino acid-defined diets. Hepatology 1996:23:755-63.
22. Matsumura Y, Sakaida I, Uchida K, et al. Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation. J Hepatol 1997:27:185-92.
23. Sakaida I, Matsumura Y, Akiyama S, et al. Herbal medicine Shosaiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 1998;28:298-306.
24. Sakaida I, Kubota M, Kayano K, et al. Prevention of fibrosis reduces enzyme-altered lesions in the rat liver. Carcinogenesis 1994;15: 2201-6.
25. Guido M, Rugge M, Chemello L, et al. Liver stellate cells in chronic viral hepatitis: The effect of interferon therapy. J Hepatol 1996;24: 301-7.
26. Caslilla A, Prieto J, Fausto N. Transforming growth factor-β1 and a in chronic liver disease. Effect of interferon alpha therapy. N Engl J Med 1991:324:933-40.
27. Capra F, Casaril M, Gabrielli GB, et al. a-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers. J Hepatol 1993:18:112-8.
28. Di Biscegli AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
29. Realdi G, Fattovich G, Pastore G, et al. Problems in the management of chronic hepatitis B with interferon: Experience in a randomized, multi-center study. J Hepatol 1990;! 1:5129-32.
30. 2b therapy reduces liver fibrosis in chronic non-A non-B hepatitis: A quantitative histological evaluation. Hepatology 1993:18:1344-9.
31. Camps J, Castilla A, Ruiz J, et al. Randomized trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol 1993:17:390-6.
32. Reichard O, Glaumann H, Fryden A, et al. Two-year biochemical, virological, and histological following up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995:21:918-22.
33. Reichard O. Short-term versus sustained response to interferon therapy: Effect on histology. Dig Dis Sei 1996;41:109S-14S.
34. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged interferon treatment to suppress relapse after cessation therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial. Hepatology 1995;21:291-7.
35. Yabu K, Kiyosawa K, Mon H, et al. Serum collagen type IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C. Scand J Gastroenterol 1994:29:474-9.